Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 1/2011

01-08-2011 | Research Letter

Low investigation rate for adrenal incidentalomas

Authors: S. Bujawansa, D. Bowen-Jones

Published in: Endocrine | Issue 1/2011

Login to get access

Abstract

The prevalence of adrenal incidentaloma has increased with the increasing use of imaging techniques. While majority are benign adenoma, a small but significant minority may be primary adrenal carcinoma or have endocrine hyper secretion. Existing guidance suggests that excess catecholamine and cortisol secretion should be ruled out in all cases and excess aldosterone secretion should be ruled out in hypertensive patients. Repeat evaluation after a period of time is also suggested. We have reviewed the management of adrenal incidentaloma in a large district general hospital in the North West of England.
Literature
1.
G. Mansmann et al., The clinically inapparent adrenal mass: update in diagnosis and management. Endocr. Rev. 25(2), 309–340 (2004)PubMedCrossRef
2.
L. Hammarstedt et al., Adrenal Study Group of Western Sweden. Adrenal lesion frequency: a prospective, cross-sectional CT study in a defined region, including systematic re-evaluation. Acta Radiol. 51(10), 1149–1156 (2010)PubMedCrossRef
3.
T.J. Cawood et al., Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? Eur. J. Endocrinol. 161(4), 513–527 (2009)PubMedCrossRef
4.
5.
I. Chiodini et al., Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism. J. Clin. Endocrinol. Metab. 95(6), 2736–2745 (2010)PubMedCrossRef
6.
NIH state-of-the-science statement on management of the clinically inapparent adrenal mass (“incidentaloma”). NIH Consens. State Sci. Statements. 19(2), 1–25 (2002)
7.
American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons Medical Guidelines for the Management of Adrenal Incidentalomas: executive summary of recommendations
8.
M.A. Zeiger et al., American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons Medical Guidelines for the Management of Adrenal Incidentalomas: executive summary of recommendations. Endocr Pract 15(5), 450–453 (2009)PubMed
9.
L.K. Nieman, Approach to the patient with an adrenal incidentaloma. J. Clin. Endocrinol. Metab. 95(9), 4106–4113 (2010)PubMedCrossRef
Metadata
Title
Low investigation rate for adrenal incidentalomas
Authors
S. Bujawansa
D. Bowen-Jones
Publication date
01-08-2011
Publisher
Springer US
Published in
Endocrine / Issue 1/2011
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-011-9487-9

Other articles of this Issue 1/2011

Endocrine 1/2011 Go to the issue

Original Article

Preimplantation factor (PIF) analog prevents type I diabetes mellitus (TIDM) development by preserving pancreatic function in NOD mice

Original Article

Influence of diabetes mellitus on vertebral fractures in men with acromegaly

Original Article

Health-related quality of life and fatigue in patients with adrenal incidentaloma

Letter to the Editor

Reply: Does Clostridium botulinum neurotoxin A exhibit molecular mimicry with thyroid autoantigens and cause thyroid complications in predisposed persons?

Original Article

Leptin cut-off values for determination of metabolic syndrome: third national surveillance of risk factors of non-communicable diseases in Iran (SuRFNCD-2007)

Original Article

Mutation prediction by PolyPhen or functional assay, a detailed comparison of CYP27B1 missense mutations
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits